title: Can we "hedge" against the development of antiviral resistance among pandemic influenza viruses?
authors: Influenza Division, United States Centers for Disease Control and Prevention, Atlanta, Georgia, USA. david.shay@cdc.hhs.gov
authors: David K
authors: DK
authors: Shay
authors: Benjamin J
authors: BJ
authors: Ridenhour
mesh_terms: D000998:Antiviral Agents / Q000600:supply & distribution / Q000627:therapeutic use; D004196:Disease Outbreaks / Q000517:prevention & control*; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D006291:Health Policy; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects; D009975:Orthomyxoviridae; D009976:Orthomyxoviridae Infections / Q000453:epidemiology / Q000517:prevention & control*; D053139:Oseltamivir / Q000600:supply & distribution / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D053139:Oseltamivir